On Tuesday, Synergy Pharmaceuticals Inc (NASDAQ:SGYP)’s shares declined -3.02% to $8.68.
Synergy Pharmaceuticals Inc. (SGYP) declared that its Chairman and Chief Executive Officer, Gary S. Jacob, Ph.D., will present a corporate update at the Canaccord Genuity 35th Annual Growth Conference on Thursday, August 13th, 2015 at 11:30 a.m. Eastern Time at the InterContinental in Boston, Massachusetts.
Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development of drugs to treat gastrointestinal (GI) disorders and diseases. Its lead product candidate is plecanatide, a guanylyl cyclase C receptor agonist that is in Phase III clinical trials to treat chronic idiopathic constipation GI disorders; and for the treatment of constipation-predominant irritable bowel syndrome GI disorders. The company is also developing SP-333, which is in Phase II clinical trials to treat opioid induced constipation, in addition to in Phase Ib clinical trials to treat ulcerative colitis. Synergy Pharmaceuticals Inc. is headquartered in New York, New York.
ABIOMED, Inc. (NASDAQ:ABMD)’s shares gained 14.73% to $88.80.
Abiomed, Inc. (ABMD), a leading provider of breakthrough heart support technologies, stated first quarter fiscal 2016 revenue of $73.4 million, an enhance of 50% contrast to revenue of $48.8 million for the same period of fiscal 2015. First quarter fiscal 2016 GAAP net income was $8.9 million or $0.20 per diluted share, contrast to GAAP net loss of $1.7 million or a loss of $0.04 per diluted share for the preceding year period.
Financial and operating highlights during the first quarter of fiscal 2016 comprise:
- Fiscal first quarter worldwide Impella® revenue totaled $68.8 million, an enhance of 53% contrast to revenue of $45.0 million during the same period of the preceding fiscal year. U.S. Impella revenue grew 60% to $63.7 million from $39.9 million in the preceding fiscal year with U.S. Impella patient usage up 62%.
- An additional 15 hospitals made initial purchases of Impella during the quarter, contrast to 24 new hospital sites in the preceding year period, bringing the installed customer base to 973 sites. As part of Abiomed’s continued Impella CP® launch, 54 new hospitals purchased Impella CP, bringing the total number of Impella CP U.S. sites to 694.
ABIOMED, Inc. researches, develops, and sells medical devices in circulatory support and continuum of care in heart recovery to acute heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; Impella CP that provides partial circulatory support using an extracorporeal bypass control unit; Impella 5.0 catheter and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; and Impella RP, a percutaneous catheter-based axial flow pump.
At the end of Tuesday’s trade, Century Aluminum Co (NASDAQ:CENX)‘s shares dipped -5.52% to $8.39.
Century Aluminum Company (CENX) declared that it intends to permanently close its Ravenswood, W.V. aluminum smelter, effective right away. The Ravenswood smelter has been idled since February 2009. The decision to permanently close the Ravenswood plant is based on the inability to secure a competitive power contract for the smelter, compounded by challenging aluminum market conditions largely driven by raised exports of aluminum from China. As a result, the economics of restarting and operating the facility are unfavorable.
Century Aluminum Company, together with its auxiliaries, produces primary aluminum in the United States and Iceland. It produces standard grade and value-added primary aluminum products; and carbon products, such as anodes and cathodes. The company was founded in 1995 and is headquartered in Chicago, Illinois.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
